These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 21881032)

  • 1. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
    Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
    Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
    Kiser TH; Fish DN
    Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
    Orzel LA; Abel EE; Blais DM; Wang TF; Porter KA; Burcham PK
    Pharmacotherapy; 2019 Dec; 39(12):1157-1166. PubMed ID: 31587337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia.
    Al-Ali FS; Elsayed M; Khalifa S; Abdulla AE; Tolba H; Bouanane H; Ibrahim R; Hamad A
    Hemodial Int; 2016 Apr; 20(2):204-7. PubMed ID: 26501237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
    Wisler JW; Washam JB; Becker RC
    J Thromb Thrombolysis; 2012 Apr; 33(3):287-95. PubMed ID: 22271374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and implementation of a nurse-driven, sliding-scale nomogram for bivalirudin in the management of heparin-induced thrombocytopenia.
    Burcham PK; Abel EE; Gerlach AT; Murphy CV; Belcher M; Blais DM
    Am J Health Syst Pharm; 2013 Jun; 70(11):980-7. PubMed ID: 23686604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study.
    Pieri M; Agracheva N; Bonaveglio E; Greco T; De Bonis M; Covello RD; Zangrillo A; Pappalardo F
    J Cardiothorac Vasc Anesth; 2013 Feb; 27(1):30-4. PubMed ID: 23036625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Optimal dose of bivalirudin in dialysis patients at high risk of heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case report].
    Notarangelo MF; Coppini L; Bontardelli F; Boffetti F; Vignali L; Ardissino D
    G Ital Cardiol (Rome); 2013 Feb; 14(2):141-4. PubMed ID: 23389318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
    Taylor LA; Mauro VF
    Ann Pharmacother; 2012 Jan; 46(1):35-41. PubMed ID: 22170973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
    Tschudi M; Lämmle B; Alberio L
    Blood; 2009 Mar; 113(11):2402-9. PubMed ID: 19059879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy.
    Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Pharmacother; 2009 Jul; 43(7):1360-5. PubMed ID: 19584380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
    Kiser TH; MacLaren R; Fish DN; Hassell KL; Teitelbaum I
    Pharmacotherapy; 2010 Nov; 30(11):1117-26. PubMed ID: 20973685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.